---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-064914"
form_type: "8-K"
ticker: null
cik: "0001061027"
company_name: "Viracta Therapeutics, Inc."
filed_at: "2023-11-17T23:59:59+00:00"
generated_at: "2026-06-07T23:49:10.196222+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Viracta receives Nasdaq minimum bid price deficiency notice; 180 days to cure

## Summary
- Nasdaq notified Viracta on Nov 15, 2023 that its common stock closing bid price was below $1.00 for 30 consecutive business days.
- Company has until May 13, 2024 to regain compliance by closing at $1.00 or more for 10 consecutive business days.
- If not compliant by May 13, Viracta may transfer to Nasdaq Capital Market and receive an additional 180-day cure period.
- The deficiency notice has no immediate impact on trading; Viracta will monitor bid price and consider available remedies.

## SEC filing metadata
- accession: 0000950170-23-064914
- form_type: 8-K
- cik: 0001061027
- company_name: Viracta Therapeutics, Inc.
- filed_at: 2023-11-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061027/000095017023064914/0000950170-23-064914-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061027/000095017023064914/virx-20231115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-064914
- JSON: https://secwatch.observer/filing/0000950170-23-064914.json
- Plain text: https://secwatch.observer/filing/0000950170-23-064914.txt

## Key facts
- Listing & Compliance Notices
  Viracta Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: November 15, 2023, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last 30 consecutive business days, the minimum bid price of the Company’s common stock had been below the $1.00 per share minimum requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 c
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017023064914/0000950170-23-064914-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.